Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations.

Authors: Kikuta, Masato, Naito, Sei, Osawa, Takahiro, Numakura, Kazuyuki, Narisawa, Takafumi, Takai, Yuki, Yagi, Mayu, Sekine, Yuya, Tokairin, Ojiro, Shinohara, Nobuo, Habuchi, Tomonori, Tsuchiya, Norihiko

Source: BMC Cancer; 1/22/2025, Vol. 25, p1-12, 12p

Subject Terms: RENAL cell carcinoma, PROGRESSION-free survival, PROTEIN-tyrosine kinase inhibitors, OVERALL survival, SURVIVAL rate

The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.

Authors: Numakura, Kazuyuki, Sekine, Yuya, Osawa, Takahiro, Naito, Sei, Tokairin, Ojiro, Muto, Yumina, Sobu, Ryuta, Kobayashi, Mizuki, Sasagawa, Hajime, Yamamoto, Ryohei, Nara, Taketoshi, Saito, Mitsuru, Narita, Shintaro, Akashi, Hideo, Tsuchiya, Norihiko, Shinohara, Nobuo, Habuchi, Tomonori

Source: International Journal of Clinical Oncology; Jul2024, Vol. 29 Issue 7, p1019-1026, 8p

Subject Terms: MONOCYTE lymphocyte ratio, RENAL cell carcinoma, OVERALL survival, PLATELET lymphocyte ratio, NIVOLUMAB, NEUTROPHIL lymphocyte ratio